Mark Leaning

Chairman, Helicon Health

Mark Leaning is an engineer and successful serial entrepreneur with a passion for transforming healthcare for the better with technology. His work spans primary care to intensive care, from prevention to the critically ill and injured, and has led to large-scale market adoption, listings, acquisitions and the development of groundbreaking products. He is Chairman of Helicon Health, which provides digital health services for both clinicians and patients to improve outcomes of chronic diseases such as atrial fibrillation, and Founder of Directed Systems Ltd, which is developing advanced decision support and closed-loop care systems to improve safety, outcomes and efficiency in critical care. Mark was CEO of Applied Physiology, a medical device company he founded whilst in Australia. Under Mark’s leadership, the company raised $15m in equity and non-dilutive grant funding and developed Navigator, an innovative and world-first CE Marked and FDA approved real-time critical care cardiovascular decision support system. Previously, as Executive Director at HCN, Australia’s leading supplier of clinical GP systems, Mark led the M&A program and played a key role in its $50m listing on the ASX. HCN was subsequently sold and realized $100m for its shareholders. Before HCN, while living in the United States, Mark was Chief Operating Officer of Preferred Health Systems, an integrated health management software company he co-founded, which was acquired by Magellan Health Services. Mark has an engineering degree from Cambridge University, followed by an MSc and PhD in Systems Engineering from City University. He is a Visiting Professor at University College London and an advisor on Industry to the UCL Institute of Digital Health. He researches and publishes on a range of subjects including biomedical engineering, mathematical modelling, artificial intelligence and digital health. Mark is also a successful inventor and product developer, having brought several new products to the health market.